Overview of #2477 — The Joe Rogan Experience with Rick Perry & W. Bryan Hubbard
This episode features former Texas Governor Rick Perry and W. Bryan Hubbard (Americans for Ibogaine) discussing the recent push to develop ibogaine into an FDA‑approved medicine in the United States. They describe a state-led “moonshot” effort (centered in Texas) to fund clinical development, legislative progress across states, early scientific and clinical signals of efficacy (especially for opioid addiction, PTSD, and certain brain injuries), and the political, spiritual and humanitarian motivations behind the movement.
Key updates & headline takeaways
- Texas has committed $100 million to the Texas Ibogaine Initiative to fund clinical development of ibogaine through the FDA process (initially proposed as $50M, later expanded).
- The Texas campaign reportedly secured overwhelming legislative support (181 of 188 legislators) and final executive approval in May 2025.
- Multiple U.S. states and jurisdictions are pursuing bills or commitments to join a multistate clinical development effort: Mississippi (signed, $5M), West Virginia (legislature passed unanimously), Kentucky (Senate passed 35–2; in House), Oklahoma (House passed; Senate pending), Louisiana (bill introduced), Tennessee (committee moved bill forward), Missouri (bills pending), plus outreach to many other states.
- Americans for Ibogaine is coordinating advocacy, ambassador outreach and partnerships (including academic and tribal engagement, and an official partnership with Gabon).
- Clinical and institutional partners mentioned: Stanford (early TBI veteran study), Center for Brain Health at UT Dallas (three‑year study led by Dr. Francesca Philby), and private treatment centers in Mexico (Ambio, Transcend).
What is ibogaine (as described on the episode)
- Ibogaine is an alkaloid extracted from the iboga shrub, native to parts of Central Africa (Gabon). It has a centuries‑long use history in Bwiti spiritual practice.
- Advocates describe ibogaine as having:
- A unique capacity to interrupt physiological substance dependence (opioids, alcohol, stimulants, tobacco) rapidly.
- Neuroregenerative / neuroplastic effects (Stanford TBI research cited).
- Benefits for trauma, PTSD, certain compulsive behaviors (e.g., gambling, compulsive eating), and some neurodegenerative or post‑concussive conditions (anecdotally).
- Acute experience is intense and often physically unpleasant (prolonged vomiting, immobility/“semi‑paralysis” for many hours); it is not a recreational drug.
Evidence, studies & claimed outcomes (summary)
- Stanford: functional MRI work on veterans after ibogaine showed rapid normalization of brain imaging in some cases; authors cited dramatic improvement in addicted brain scans within 72 hours (per the interview).
- Early veteran study (n≈30) referenced: ~87% PTSD resolution at six months (claimed by speakers) and high rates of addiction interruption.
- Claimed efficacy figures in the discussion: ~85% opioid “clean” after a single application; up to ~98% with two doses (these are speaker claims and should be considered preliminary until reproduced in rigorous, controlled trials).
- UT Dallas Center for Brain Health will run a three‑year study focused on veterans to determine: who benefits, how long benefits last, which functional domains improve (cognition, sleep, substance use, well‑being), and brain‑change correlates.
Policy, legal and organizational landscape
- Americans for Ibogaine (Perry/Hubbard et al.) is organizing a multi‑state, state‑funded path to generate clinical trial data and drive federal action.
- Federal obstacles:
- Ibogaine is Schedule I in the U.S.; advocates want rescheduling (to Schedules II–III) or policy action enabling accelerated clinical development.
- DEA interpretation currently blocks use of the federal “Right to Try” pathway for Schedule I agents; advocates call for the DEA to reverse that interpretation and for presidential action (rescheduling/directives) to accelerate access and federal collaboration.
- Tribal interest: Choctaw Nation and other tribes are exploring partnerships and possible sovereign pathways to provide treatment.
- International partner: Government of Gabon named Americans for Ibogaine its official partner for advancing iboga medicine globally.
Notable personal testimonies & examples cited
- Marcus and Morgan Luttrell (twins; veterans) as prominent advocates who influenced Texas leadership.
- Governor Rick Perry described personal experience: underwent ibogaine treatment (not in the Stanford trial), reporting a 27% increase in prefrontal activity one week later and reversal of brain atrophy at six months (per scans reviewed by a neurosurgeon he quoted).
- Stories of dramatic recoveries (presented anecdotally): veterans with TBI/PTSD, survivors of sexual abuse, first responders, professional athletes with suspected CTE, and a person claiming recovery from early‑onset Parkinson’s symptoms after ibogaine.
- Former public figures and military leaders (Rear Admiral Jim Hancock, General Glenn Curtis) are engaged as ambassadors.
Risks, limitations and important caveats
- Research status: much of the evidence presented is early, open‑label, or anecdotal; rigorous randomized controlled trials and larger safety datasets are needed.
- Safety concerns: speakers acknowledge intense acute effects (vomiting, immobility) and recommend that ibogaine not be a first‑line treatment; it must be administered under medical supervision. (Note: outside this episode, ibogaine is known to carry cardiotoxic risks and can interact dangerously with other medications—medical oversight and screening are critical.)
- Regulatory barriers remain significant (Schedule I status, DEA positions) and could slow clinical implementation even with state funding.
- Supply and cultivation: iboga is climate/soil dependent; quality/varieties differ (Gabonese strains, “real” vs. “poison imposter” plants), so supply chain and quality control are logistical challenges.
Action items suggested by guests (how listeners can help / what’s next)
- Support or engage with Americans for Ibogaine (advocacy, donations, ambassador work).
- Contact state legislators if you live in states with pending bills (e.g., Missouri, Kentucky House, Louisiana) to encourage joining multistate initiative.
- Follow and support scientific trials (UT Dallas Center for Brain Health study, Stanford work) and demand rigorous, transparent data.
- Pressure federal agencies and elected leaders to:
- Clarify DEA interpretation of Right‑to‑Try for investigational Schedule I agents,
- Consider rescheduling or executive actions to speed research access,
- Provide federal support and funding for trials.
- If considering treatment personally: research clinical trials and regulated protocols, and consult qualified medical professionals; avoid unsupervised or unregulated treatment settings.
Notable quotes
- “If we have within our grasp here a compound that can heal our loved ones who have an addiction…we owe it to them.” — Rick Perry
- “This is the moonshot of our time.” — W. Bryan Hubbard / Rick Perry (repeated framing)
- “Ibogaine confirms without question the reality of our individual human divinity.” — W. Bryan Hubbard (reflecting the spiritual framing used in advocacy)
- “We are desperate and we are determined…The truth is marching on.” — W. Bryan Hubbard (closing remarks)
Bottom line
This episode lays out an ambitious state‑led strategy to develop ibogaine into an FDA‑approved therapeutic for addiction, PTSD, TBI and other conditions, anchored by Texas’s large funding commitment and an expanding multi‑state coalition. Early clinical and anecdotal signals of efficacy are compelling according to the guests, but substantial scientific validation, safety data, regulatory change, and supply‑chain/workforce development remain necessary before broad clinical integration is possible. The movement mixes scientific, political, moral and spiritual arguments and is actively mobilizing legislation, academic studies, and public advocacy to accelerate progress.